WEBULL
WebtradeDownload

First U.S. Brain Scan Doses Could Be A Game Changer For Telix Pharmaceuticals (ASX:TLX)

Simply Wall St · 2d ago
  • In recent weeks, Telix Pharmaceuticals reported the first U.S. patients dosed with Pixclara for glioma imaging, secured FDA Fast Track designation for its BiPASS prostate cancer study, and was named in a co-education agreement announced by Profound Medical to promote PSMA PET and MRI guided prostate care.
  • Taken together, these updates highlight Telix Pharmaceuticals pushing its diagnostics deeper into clinical workflows while partnering to integrate imaging data directly into treatment planning. This may affect how frequently its products are used per patient.
  • We will now look at how Telix Pharmaceuticals' investment narrative could shift as Pixclara begins U.S. dosing in routine glioma imaging.

Scan 8 healthcare AI stocks that, like Telix Pharmaceuticals, are pushing advanced imaging and AI driven tools deeper into real clinical workflows for oncology care.

Telix Pharmaceuticals Investment Narrative Recap

To be comfortable owning Telix Pharmaceuticals, you need to believe its radiopharmaceutical platform can keep expanding across urology, neuro oncology and manufacturing without eroding profitability. The main near term swing factor is how efficiently Telix turns growing use of Illuccix, Gozellix and Pixclara into cash, given heavy R&D and infrastructure spend already weighs on adjusted EBITDA and debt is not well covered by operating cash flow.

The biggest risk remains execution strain from running multiple late stage trials while integrating lower margin manufacturing assets like RLS. The latest Pixclara and prostate workflow updates look additive to the precision imaging story but do not yet change the core risk that pricing pressure, regulatory processes and trial outcomes could keep margins and earnings under pressure.

The co education agreement with Profound Medical looks most relevant here because it plugs Illuccix and Gozellix deeper into real world prostate treatment planning. Education programs across urologists, radiologists and nuclear medicine physicians can support awareness of PSMA informed pathways, which matters if Telix wants BiPASS data and existing indications to translate into higher scan volumes per patient rather than just more geographic reach.

Operationally, the planned PSMA PET MR image fusion into Profound’s TULSA PRO console aligns with Telix’s push to move PSMA imaging earlier in the biopsy decision. That directly intersects with the BiPASS Fast Track program, since clearer pre biopsy imaging can be a practical catalyst for protocol change, but it also concentrates risk in prostate, where competitive pressure, reimbursement shifts and the SEC subpoena already sit in the background.

Telix Pharmaceuticals' current analyst narrative assumes revenues reach $1.4b and earnings come to $62.5 million by 2029, based on forecast revenue growth of 14.9% per year and an earnings increase of about 86% from $33.5 million today to the 2029 consensus level.

Uncover why Telix Pharmaceuticals' fair value indicates a 55% potential upside to its current price, which could narrow quickly.

ASX:TLX 1-Year Stock Price Chart
ASX:TLX 1-Year Stock Price Chart

Exploring Other Perspectives

One alternate view puts far more weight on Telix Pharmaceuticals turning this imaging footprint into future therapeutics income. Those bullish analysts were already pencilling in about $1.9b of revenue and $420.8 million of earnings by 2029 before this Pixclara and BiPASS news. That is a much more optimistic story. Use it as a reference point and compare several narratives for yourself.

Explore 6 other Telix Pharmaceuticals fair value estimates, including one that suggests potential upside of up to 164% from the current price.

Form Your Own Verdict

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking For More Investment Ideas Beyond Telix Pharmaceuticals?

If Telix Pharmaceuticals has sharpened your interest in healthcare and beyond, broaden your watchlist by scanning other companies through the Simply Wall St Screener. You can filter by quality, balance sheet strength or income focus so you are not just reacting to headlines but building a watchlist that fits your approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.